This week Dr Ray O’Connor considers some recent papers which touch on disease prevention ...
The study evaluates artificial sweeteners' role in appetite regulation, showing no significant effects on hunger or energy ...
More than 1,000 survey respondents suggest that a lot of people might already be thinking about reducing their meat intake ...
Opinion piece by Anders Bjarklev, President of DTU - Brian Mikkelsen, CEO of Danish Chamber of Commerce - Kristian Jensen, CEO of Green Power Denmark ...
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic ...
What’s the best way to manage your cholesterol? Drawing on decades of research, a world-leading heart-health doctor explains what works ...
Genes are only part of your story.
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disorders Lexicon has earned a second of three potential ...
Zacks Investment Research on MSN
LXRX stock up as NVO initiates phase I study of partnered obesity drug
Shares of Lexicon Pharmaceuticals LXRX gained 5.1% on Monday after the company announced that its partner, Novo Nordisk NVO, ...
Not all people at high risk of developing cancer ever do, but we don’t know much about why. Now, a team of researchers is seeking to understand this in the hope that it could revolutionise prevention ...
Blood pressure is one of the most important signs of heart health, yet many people do not fully understand what the numbers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results